What Syqe Medical does

Syqe Medical Ltd. is an Israeli med-tech company founded in 2011 that has developed the SyqeAir platform, the world's first metered-dose medical cannabis inhaler. The system combines a proprietary electromechanical inhaler (featuring Electronic Selective-Dose™, ActiveFlow™, and PulseBreath™ mechanisms) with single-use SyqeAir Cartridges containing 60 standardized doses of full-spectrum Bedrocan cannabis, and a companion mobile app for treatment management. The technology delivers precise 250–1,000 microgram THC doses per inhalation, which the company reports results in 79x lower daily THC exposure, 90% fewer adverse effects, and 92% of patients reporting quality-of-life improvement in real-world evidence from over 1,249 patients.

Syqe generates revenue through hardware (inhaler device) and recurring cartridge sales distributed via exclusive pharmaceutical partners — Teva in Israel and Novachem in Australia — supplemented by direct pharmacy and app-based reordering. The company has obtained regulatory approvals in Israel (AMAR/MDL/CE), Canada (Health Canada, 2021), and Australia (TGA, 2023), and became the first Israeli company to receive EU-GMP certification for a cannabis inhalation product in January 2024. The company targets multiple patient segments, with chronic neuropathic pain as the primary indication (53% of Israel's 123,714 medical cannabis licensees), and has secured government-backed veteran access programs in both Israel (Ministry of Defense, 2023) and Australia (DVA, 2025). The company has raised $83 million cumulatively through investors including Shavit Capital and Philip Morris International, holds over 160 patents, and is currently expanding into European markets including Germany, the UK, and Denmark.

Name

Syqe Medical

Legal name

Syqe Medical Ltd.

Website

https://syqe.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

Syqe Medical is an Israeli med-tech company that has developed the SyqeAir, the world's first metered-dose medical cannabis inhaler, serving chronic pain, PTSD, oncology, and veteran patients across Israel, Australia, Canada, and select EU markets with pharmaceutical-grade precision dosing.

Ownership category

akta.pro rank

Product category

Medical Cannabis Inhalation Devices

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Inhalers (MDI/DPI/SMI) (HLAHAIAI)

Keywords

• Metered-dose inhalers
• Medical cannabis devices
• Pharmaceutical inhalation systems
• Cannabis drug delivery
• Precision dose inhalers

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SyqeAir Inhaler Device Sales: Sale of the SyqeAir medical inhaler device - a hardware product that enables precise metered-dose medical cannabis administration.
2. SyqeAir Cartridge Sales: Recurring sales of proprietary cartridges containing 60 metered doses each. Each cartridge uses Bedrocan® standardized cannabis. Cartridges can be ordered directly from pharmacies through the SyqeAir App.
3. Clinical Trial Services: Syqe Medical serves as international sponsor for clinical trials, operating under fee-for-service arrangements with CROs. The company conducts clinical trials to demonstrate effectiveness and safety of the SyqeAir inhaler.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Syqe Medical manufactures and sells the SyqeAir system, a prescription-only metered-dose medical cannabis inhaler platform. The system consists of the SyqeAir Inhaler device, proprietary SyqeAir Cartridges (each containing 60 pre-measured doses of standardized Bedrocan cannabis), the SyqeAir companion mobile app, and a nurse-guided Patient Support Program for personalized dosing. It delivers precise THC doses (250-1000 mcg) for chronic neuropathic pain, PTSD, and oncology symptom management with minimal psychoactive effects.

Product overview

Syqe Medical is a MedTech company offering the SyqeAir system — a comprehensive medical cannabis treatment platform comprising the SyqeAir Metered-Dose Inhaler (the world's first metered-dose cannabis inhaler), proprietary SyqeAir Cartridges containing 60 doses of Bedrocan standardized cannabis, the SyqeAir companion mobile app, and nursing-guided Patient Support Program. The system applies pharmaceutical-grade principles to medical cannabis delivery, enabling precise dosing (250-1000 mcg THC), consistent therapeutic effects, and reduced psychoactive side effects compared to traditional routes of administration. The company holds EU-GMP certification and regulatory approvals in Israel, Australia, and Canada.

Differentiator

Problem solved

Functional benefit

Brands

• SyqeAir: The flagship product - a metered-dose medical cannabis inhaler that delivers precise, consistent, and low doses of THC for treatment of chronic neuropathic pain with minimal psychoactive effects.
• SyqeAir Cartridge
• SyqeAir App

Quantifiable outcome

• 92% of patients report quality of life improvement
• +6 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature7 records

Partnerships

Seven partnerships are on record, tiered core, regional and minor.

• Israeli Ministry of DefensecoreStrategic or Co-development Partner · 15 February 2023First-of-its-kind agreement to supply SyqeAir Inhaler and Cartridges to all veterans prescribed medical cannabis. Government partnership enabling veteran access to precise dosing medical cannabis treatment.
• Teva PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 January 2016Exclusive marketing and distribution agreement signed in 2016 for the Israeli market. Teva markets SyqeAir inhalers exclusively in Israel, leveraging their established pharmaceutical distribution network and relationships with healthcare providers.
• BedrocancoreStrategic or Co-development PartnerExclusive Israeli importer of Bedrocan® pharmaceutical-grade medicinal cannabis. Bedrocan provides standardized cannabis with reproducible composition from batch to batch, grown under EU-GMP conditions. This partnership ensures consistent therapeutic effect and supply chain quality.
• NovachemregionalChannel Partner/ Reseller/ DistributorAustralian distributor providing metered-dosing inhaler to patients following TGA approval. Novachem handles distribution logistics and regulatory compliance for the Australian market.
• Syneos HealthminorImplementation/ SI/ Consulting PartnerAustralian CRO (Contract Research Organization) engaged for clinical trial operations. Syneos operates under fee-for-service arrangements for international sponsor Syqe Medical's clinical trials.
• NICM Health Research (Western Sydney University)minorImplementation/ SI/ Consulting PartnerParticipant-recruitment site for international clinical trial investigating medicinal cannabis for diabetic peripheral neuropathy. Operating under fee-for-service arrangement with Syneos.
• Australian Department of Veterans' Affairs (DVA)regionalChannel Partner/ Reseller/ DistributorGovernment funding scheme enabling eligible Australian veterans to access SyqeAir treatment at no cost following TGA approval. DVA subsidies cover device and cartridge costs for approved veterans.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Panaxia Pharmaceutical Industries: Israeli pharmaceutical-grade medical cannabis manufacturer producing standardized dosage formats. Directly comparable to Syqe as a domestic Israeli competitor pursuing pharma-grade cannabis products with EU-GMP ambitions.
• STENOCARE: Danish-listed medical cannabis company focused on prescription-grade cannabinoid products in European markets. Comparable to Syqe's regulated, pharmaceutical-grade positioning and EU expansion strategy.
• Cannamedical Pharma: German pharmaceutical-grade medical cannabis supplier with EU-GMP certification and a focus on pharmacy-channel distribution. Comparable business model centered on pharma-grade cannabis in regulated European markets.

Others

• Bedrocan: Dutch producer of standardized pharmaceutical-grade cannabis and Syqe's exclusive cannabis supplier. Comparable due to its standardized, batch-reproducible cannabis positioning and EU-GMP cultivation.
• Vectura Fertin Pharma: Philip Morris International subsidiary focused on inhalation drug delivery technology and a historical investor/partner of Syqe. Comparable as a strategic peer in metered-dose inhalation technology and a connected party in Syqe's cap table.

Broad incumbents

• Jazz Pharmaceuticals: Acquired GW Pharmaceuticals and Epidiolex, becoming a leading pharmaceutical company with FDA-approved cannabinoid medicines. Comparable as a large incumbent bringing prescription-grade cannabis products to global markets.
• Tilray Brands: Global cannabis company with a medical cannabis division across multiple countries. Comparable as a broad incumbent offering medical cannabis products in markets where Syqe also operates or targets.
• Canopy Growth: Large multi-jurisdiction cannabis operator with a Spectrum Therapeutics medical cannabis portfolio. Comparable as a broad incumbent competing in medical cannabis markets where Syqe is approved or expanding.
• Aphria / Aurora Cannabis: Major medical cannabis producers with operations in Canada, Australia, and Europe. Comparable as incumbents in the same regulated geographies Syqe has secured approvals in.
• Cipla: Global pharmaceutical company with deep expertise in metered-dose inhalers (MDI/DPI) for respiratory conditions. Comparable on the drug delivery inhaler technology axis, with potential adjacent applicability to cannabis delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/syqe-medical-ltd

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syqe Medical